Superior Clinical, Quality of Life, Functional, and Health Economic Outcomes with Pneumatic Compression Therapy for Lymphedema

Peer Reviewed Scientific Publication

Home/Publications and Presentations/Pneumatic Compression Therapy for Lymphedema

Background

Pneumatic compression therapy is one of several options for the management of lymphedema. The lack of clarity around clinical outcomes, quality of life, cost of care, and its proper application, as a function of lymphedema complexity, limit its use in clinical practice. This is compounded by difficulties associated with insurance approval and uncertainty about the role of this modality in the treatment algorithm. The purpose of this study is to elucidate the healthcare economics and value of pneumatic compression therapy for lymphedema.

Recent Posts

  • A screenshot of the Lancet paper discussing hydroxychloroquine and COVID-19

Follow up on our Lancet paper

May 25th, 2020|0 Comments

Follow up on our Lancet paper Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis We, at Surgisphere, appreciate the enthusiasm [...]

Methods

All patients who underwent treatment for lymphedema at a single institution were followed prospectively over a 2-year period. Patient demographics, comorbidities, treatment modality, and treatment efficacy were determined. Direct costs over the 2-year period, inclusive of hospitalization and device costs, SF-36 quality of life, and leg lymphedema complexity score (LLCS), were measured.

Results

A total of 128 patients were enrolled over a period of 3 years for a total of 232 extremities treated for secondary lymphedema. Pneumatic compression therapy was utilized for all patients and led to a 28% decrease in absolute limb volume (P < 0.001), decrease in body mass index (BMI) (P < 0.001), significant improvement in SF-36 quality of life in 7 out of 8 domains (P < 0.001), and a significant improvement in LLCS (P < 0.001) at 1 year. A subsequent decrease in hospitalization for lymphedema-associated complications saved over $3,200 per patient per year.

0%
Decrease in absolute limb volume
P < 0
Decrease in BMI
$0
Decrease in Costs

Conclusions

Pneumatic compression therapy leads to improved clinical outcomes, quality of life, and functional status for clinically significant lymphedema. Significant per capita direct cost savings, a beneficial impact on pay for performance measures, and a reduction in lymphedema related complications suggest that earlier adoption of this treatment modality may offer a superior value proposition to patients, physicians, hospitals, and the healthcare system.

Events

Midwestern Vascular Surgical Society

September 10 @ 8:00 am - September 12 @ 5:00 pm

Data Acquisition
Data Warehousing
Data Analytics
Data Reporting

Related Posts

Get started with our industry leading solutions today

Looking for help? Get in touch with us

By |2020-03-22T03:25:34-05:00January 15th, 2020|Publications and Presentations|0 Comments

About the Author: